2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Study Population, Human, Adult
PAPER

2107 Pattern of clonal hematopoiesis mutations in chronic lymphocytic leukemia reveals potentially new mechanistic insights

Thomas Deere, Kate Quinn2, Chia Sharpe, PhD3, Ben Wronowski4, Katelyn Michelle Melgar, MD, PhD5, Megan E. Johnstone, PhD6, John Byrd, MD7, Erin Hertlein, PhD8
1 University of Cincinnati, Cincinnati, Ohio, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University of Cincinnati, Cincinnati, Ohio, United States
4 University of Cincinnati, Cincinnati, Ohio, United States
5 University of Cincinnati, Cincinnati, Ohio, United States
6 University of Cincinnati, Cincinnati, Ohio, United States
7 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 University of Cincinnati, Cincinnati, Ohio, United States

Clonal hematopoiesis (CH) is the clonal outgrowth of hematopoietic stem and progenitor cells (HSPCs) that accumulate somatic mutations often associated with age. While these CH mutations can represent a pre-leukemic state and specific mutations have been associated with myeloid disease (ASXL1, DNMT3A, TET2, PPM1D, TP53, SF3B1, JAK2, U2AF1) and lymphoid disease (ATM, MyD88, NOTCH1, PTEN, XPO1) (Niroula et al. 2021), a thorough investigation into the cellular subset restriction of CH mutations has not been explored. Our hypothesis is that the specific cellular context of these mutations will have direct implications on the tumor microenvironment and outcomes in leukemia. Our results here suggest a distinct pattern of CH associated mutations in CLL, highlighting potentially novel functional implications in both the leukemic B cells as well as the leukemia associated immune cells.

We performed Tapestri (Mission Bio®) single-cell DNA sequencing and immunophenotyping on peripheral blood mononuclear cells (PBMCs) from 44 CLL patients with myeloid and/or lymphoid CH mutations previously identified by commercial sequencing panels. To better incorporate both myeloid and lymphoid associated CH mutations, we designed our own custom panel. For cell immunophenotyping, we used the TotalSeqTM -D Heme Oncology Cocktail (Biolegend). We followed the Tapestri v3 protocol which utilizes a microfluidic, droplet-based platform to barcode the cells that then undergo PCR amplification. DNA and protein libraries were sequenced using the Illumina NovaSeqX instrument. We performed data analysis and created figures using the Mission Bio Mosaic v3.17 pipeline. To differentiate between the myeloid and lymphoid (T cells, B cells, leukemic B cells) compartment in our analysis, we defined the following immunophenotyping categories: myeloid (CD3-, CD8-, CD19-, CD14+), NK cell (CD3-, CD14-, CD16-, CD19-, CD56+), T cell (CD14-, CD19-, CD3+, CD56+), B cell (CD3-, CD14-, CD56-, CD5-, CD19+), and leukemic B cell (CD3-, CD14-, CD56-, CD5+, CD19+).

We found that mutations typically associated with lymphoid CH were restricted to the lymphoid compartment while mutations typically associated with myeloid CH were more broadly represented. The presence of myeloid CH mutations were identified in both the myeloid/lymphoid lineage (ASXL1: n=3; DNMT3A: n=4; TET2: n=7; PPM1D: n=2; SF3B1: n=1; TP53: n=1; U2AF1: n=1) or myeloid lineage only (ASXL1: n=2; DNMT3A: n=1; PPM1D: n=2; TET2: n=4; U2AF1: n=1). DNMT3A and TET2 mutations never occurred in the leukemic B-cell clone. However, we verified that ASXL1 (n=4) (Cosentino et al. 2026), KRAS (n=2), SF3B1 (n=5), TP53 (n=7), and PPM1D (n=2) mutations could occur in the leukemic B-cell clone, but interestingly these are not concurrently present in the myeloid cells in these patients. As expected, when ASXL1, KRAS, SF3B1, TP53, and PPM1D were present in the leukemic clone they co-occurred with other B-cell leukemia associated mutations (BRAF, NOTCH1, XPO1).

To determine whether specific CH mutations are restricted to a particular cell type in CLL, we performed Tapestri single-cell DNA sequencing with cell immunophenotyping of 44 CLL patients. We identified PPM1D mutations occur in leukemic B cells, but not concurrently in the myeloid cells. Additionally, we revealed that some CH mutations can be completely excluded from the leukemic B-cell clone but are present in other cell types. The novel discovery that PPM1D mutations can occur in the leukemic clone of CLL patients will require further study into a potential mechanism of how PPM1D mutations contribute to CLL pathogenesis. Additionally, we revealed that some CH mutations are excluded from the leukemic B cells suggesting that the leukemia developed first, and CH could be secondary to leukemia initiation in CLL patients.

Thomas Deere: No relevant conflicts of interest to declare.